Media stories about Medidata Solutions (NASDAQ:MDSO) have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than 6,000 news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medidata Solutions earned a media sentiment score of 3.43 on their scale. InfoTrie also assigned media headlines about the company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have effected Medidata Solutions’ score:
- Medidata Solutions (NASDAQ:MDSO) Downgraded by Piper Jaffray Companies (americanbankingnews.com)
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Medidata Solutions, Inc. (prnewswire.com)
- Dassault Systemes to buy Medidata Solutions in US$5.8b deal (msn.com)
- Dassault Systemes to acquire Medidata for $5.8B (massdevice.com)
- Dassault Systèmes To Buy Medidata Solutions In $5.8 Bln Deal – Quick Facts (markets.businessinsider.com)
A number of research analysts recently issued reports on MDSO shares. Zacks Investment Research downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a report on Monday, February 18th. TheStreet upgraded Medidata Solutions from a “c+” rating to a “b-” rating in a report on Friday, March 15th. BidaskClub upgraded Medidata Solutions from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 20th. William Blair started coverage on Medidata Solutions in a report on Monday, April 15th. They set an “outperform” rating and a $74.93 price target on the stock. Finally, Guggenheim started coverage on Medidata Solutions in a report on Wednesday, April 17th. They set a “buy” rating and a $92.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $84.24.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Tuesday, April 30th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. Medidata Solutions had a return on equity of 9.28% and a net margin of 7.99%. The firm had revenue of $173.50 million for the quarter, compared to the consensus estimate of $172.12 million. During the same quarter in the prior year, the business earned $0.40 EPS. The business’s revenue for the quarter was up 16.3% on a year-over-year basis. On average, analysts expect that Medidata Solutions will post 0.79 EPS for the current year.
In other news, Director Robert Taylor sold 3,294 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $90.88, for a total value of $299,358.72. Following the sale, the director now directly owns 41,757 shares of the company’s stock, valued at approximately $3,794,876.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.70% of the stock is currently owned by corporate insiders.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Article: What are the Benefits of Index Funds?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.